Zacks: Analysts Expect Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Earnings of -$1.09 Per Share

Wall Street brokerages expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report ($1.09) earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have issued estimates for Acorda Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.29) and the highest estimate coming in at ($0.96). Acorda Therapeutics reported earnings of $1.40 per share during the same quarter last year, which indicates a negative year over year growth rate of 177.9%. The firm is expected to report its next earnings results on Thursday, August 1st.

On average, analysts expect that Acorda Therapeutics will report full year earnings of ($3.59) per share for the current fiscal year, with EPS estimates ranging from ($4.29) to ($3.26). For the next year, analysts expect that the firm will post earnings of ($3.09) per share, with EPS estimates ranging from ($4.28) to ($2.56). Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.51. The company had revenue of $44.14 million during the quarter, compared to analysts’ expectations of $35.14 million. Acorda Therapeutics had a positive return on equity of 9.34% and a negative net margin of 1.40%. The firm’s revenue was down 58.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.14 EPS.

Several equities analysts have recently weighed in on the company. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Oppenheimer set a $13.00 target price on Alpine Immune Sciences and gave the company a “buy” rating in a research report on Tuesday, March 19th. JPMorgan Chase & Co. reiterated a “sell” rating and issued a $60.00 price target on shares of Bayerische Motoren Werke in a report on Tuesday, May 7th. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Finally, Wedbush set a $190.00 price target on Home Depot and gave the company a “hold” rating in a report on Wednesday, May 22nd. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $19.03.

Shares of NASDAQ ACOR traded up $0.35 during midday trading on Thursday, hitting $6.91. The stock had a trading volume of 30,568 shares, compared to its average volume of 838,097. The company has a market cap of $318.62 million, a P/E ratio of 3.77 and a beta of 1.15. Acorda Therapeutics has a 1-year low of $6.43 and a 1-year high of $30.25. The company has a quick ratio of 3.97, a current ratio of 4.30 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average of $7.80.

Large investors have recently bought and sold shares of the stock. Texas Permanent School Fund raised its position in shares of Acorda Therapeutics by 3.9% in the 1st quarter. Texas Permanent School Fund now owns 26,844 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 1,013 shares in the last quarter. Comerica Bank lifted its position in Acorda Therapeutics by 2.8% in the 1st quarter. Comerica Bank now owns 39,284 shares of the biopharmaceutical company’s stock valued at $502,000 after purchasing an additional 1,053 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Acorda Therapeutics by 45.8% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 4,106 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 1,289 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Acorda Therapeutics by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 327,281 shares of the biopharmaceutical company’s stock worth $5,099,000 after buying an additional 1,841 shares in the last quarter. Finally, Clearbridge Investments LLC raised its position in shares of Acorda Therapeutics by 0.4% during the 1st quarter. Clearbridge Investments LLC now owns 787,035 shares of the biopharmaceutical company’s stock worth $10,460,000 after buying an additional 2,764 shares in the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Featured Story: Gap Down Stocks

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.